Weeks after it released positive data on an early-stage study of its experimental gene therapy for HIV, VIRxSYS has raised $20 million in a series G round of financing. Some of that money will be used to support a Phase II trial of VRX496 for HIV. VRX496 relies on an HIV-based lentiviral vector--or viral container--from which the disease-causing aspects of the virus have been removed, leaving behind an efficient gene-delivery vehicle. VIRxSYS then equips the vector with a long antisense sequence against the HIV envelope protein to create VRX496.
- check out the release on the new round